These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 12704813)
21. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559 [TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286 [TBL] [Abstract][Full Text] [Related]
23. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261 [TBL] [Abstract][Full Text] [Related]
24. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages. Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118 [TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043 [TBL] [Abstract][Full Text] [Related]
26. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783 [TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910 [TBL] [Abstract][Full Text] [Related]
29. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035 [TBL] [Abstract][Full Text] [Related]
30. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854 [TBL] [Abstract][Full Text] [Related]
31. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease. Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578 [TBL] [Abstract][Full Text] [Related]
32. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294 [TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505 [TBL] [Abstract][Full Text] [Related]
35. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538 [TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339 [TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Compta Y; Martí MJ; Ibarretxe-Bilbao N; Junqué C; Valldeoriola F; Muñoz E; Ezquerra M; Ríos J; Tolosa E Mov Disord; 2009 Nov; 24(15):2203-10. PubMed ID: 19795497 [TBL] [Abstract][Full Text] [Related]
38. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Munroe WA; Southwick PC; Chang L; Scharre DW; Echols CL; Fu PC; Whaley JM; Wolfert RL Ann Clin Lab Sci; 1995; 25(3):207-17. PubMed ID: 7605102 [TBL] [Abstract][Full Text] [Related]
39. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease]. Hu Y; He S; Wang J Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632 [TBL] [Abstract][Full Text] [Related]
40. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]